Literature DB >> 14871986

Genetic pathways and new progression markers for prostate cancer suggested by microsatellite allelotyping.

Rolf von Knobloch1, Lutz Konrad, Peter J Barth, Heidrun Brandt, Sebastian Wille, Axel Heidenreich, Roland Moll, Rainer Hofmann.   

Abstract

PURPOSE: At diagnosis, the biological behavior of prostate cancer is uncertain, making the choice of an adequate therapy option difficult. Performing microsatellite allelotyping on a large series of consecutive prostate cancers procured during radical prostatectomy at our institution, we sought to identify molecular markers associated with disease progression. EXPERIMENTAL
DESIGN: A total of 156 consecutive fresh tumor samples was prospectively collected and macroscopically dissected from the whole prostatectomy specimen immediately after operation. Histologically 100 samples contained >75% tumor cells and were therefore enrolled in the microsatellite allelotyping, using a total of 24 polymorphic markers for the chromosomal regions 5p, 5q, 7q, 8p, 9p, 9q, 13q, 17p, 17q, and 18q. Fresh paired normal and tumor DNA was investigated in fluorescent microsatellite analysis with automated laser product detection.
RESULTS: The incidence of tumor-DNA alterations [loss of heterozygosity or allelic imbalance (AI)] was highest for chromosomal regions 13q and 8p with 72 and 71%, respectively, followed by chromosomes 7q, 18q, 5q, and 17p with 57, 53, 41, and 39%, respectively. Alterations at chromosomes 8p, 9p, 13q, and 17p were significantly (P < 0.05) associated with advanced tumor stage, whereas AI at 8p and 17p was also associated with high Gleason score (P < 0.05). AI at 5q and 9p was associated with regional lymph node metastasis (P < 0.05). The combination of AI at 8p and 13q was strongly associated with advanced tumor stage (P < 0.0001).
CONCLUSIONS: With the obtained results, we are able to postulate three distinct pathways in prostate carcinogenesis, and we identified microsatellite markers of prognostic value.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14871986     DOI: 10.1158/1078-0432.ccr-03-0070

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  6 in total

1.  [Research in urologic university clinics. Assessment of current status and perspectives].

Authors:  K Miller; H Krause
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

2.  Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer.

Authors:  Maximilian Burger; Stefan Denzinger; Christine G Hammerschmied; Andrea Tannapfel; Ellen C Obermann; Wolf F Wieland; Arndt Hartmann; Robert Stoehr
Journal:  J Mol Med (Berl)       Date:  2006-08-03       Impact factor: 4.599

Review 3.  Signal transducer and activator of transcription 5A/B in prostate and breast cancers.

Authors:  Shyh-Han Tan; Marja T Nevalainen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

4.  STAT5A/B gene locus undergoes amplification during human prostate cancer progression.

Authors:  Bassem R Haddad; Lei Gu; Tuomas Mirtti; Ayush Dagvadorj; Paraskevi Vogiatzi; David T Hoang; Renu Bajaj; Benjamin Leiby; Elyse Ellsworth; Shauna Blackmon; Christian Ruiz; Mark Curtis; Paolo Fortina; Adam Ertel; Chengbao Liu; Hallgeir Rui; Tapio Visakorpi; Lukas Bubendorf; Costas D Lallas; Edouard J Trabulsi; Peter McCue; Leonard Gomella; Marja T Nevalainen
Journal:  Am J Pathol       Date:  2013-05-07       Impact factor: 4.307

5.  What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.

Authors:  Andrea Palicelli; Stefania Croci; Alessandra Bisagni; Eleonora Zanetti; Dario De Biase; Beatrice Melli; Francesca Sanguedolce; Moira Ragazzi; Magda Zanelli; Alcides Chaux; Sofia Cañete-Portillo; Maria Paola Bonasoni; Alessandra Soriano; Stefano Ascani; Maurizio Zizzo; Carolina Castro Ruiz; Antonio De Leo; Guido Giordano; Matteo Landriscina; Giuseppe Carrieri; Luigi Cormio; Daniel M Berney; Jatin Gandhi; Valerio Copelli; Giuditta Bernardelli; Giacomo Santandrea; Martina Bonacini
Journal:  Int J Mol Sci       Date:  2021-11-15       Impact factor: 5.923

6.  Diagnostic value of DNA alteration: loss of heterozygosity or allelic imbalance-promising for molecular staging of prostate cancers.

Authors:  Magdalena Bryś; Monika Migdalska-Sęk; Dorota Pastuszak-Lewandoska; Ewa Forma; Karolina Czarnecka; Daria Domańska; Ewa Nawrot; Jacek Wilkosz; Waldemar Różański; Ewa Brzeziańska
Journal:  Med Oncol       Date:  2013-01-04       Impact factor: 3.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.